In general, for most solid tumors, a tissue diagnosis is made prior to the performance of PET scanning. The PET results may assist in avoiding an invasive diagnostic procedure, or the PET results may assist in determining the optimal anatomic location to perform an invasive diagnostic procedure. PET-CT Fusion: The fusion of PET and CT imaging into a single system (PET/CT fusion) is considered medically necessary for any oncologic indication where PET scanning is considered medically necessary. T-cell lymphoma (includes peripheral T-cell lymphoma, Mycosis Fungoides/Sézary Syndrome, primary cutaneous CD30+ T-cell lymphoproliferative disorders).Post-transplant lymphoproliferative disorder.Non-Hodgkin's lymphoma (for select subtypes, see section II.B.8.).Head and neck cancers (excluding cancers of the central nervous system).Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with suspected Richter's transformation.The fusion of PET and CT imaging into a single system (PET/CT fusion) is considered experimental and investigational for cardiac indications a PET scan without CT is adequate to evaluate the myocardium (NIA, 2005).Īetna considers FDG-PET medically necessary for the following oncologic indications, when the following general and disease-specific criteria for diagnosis, staging, restaging and/or monitoring are met, and the FDG-PET scan is necessary to guide management: Diagnostic tests such as FDG-PET distinguish between dysfunctional but viable myocardial tissue and scar tissue in order to affect the management decisions in members with ischemic cardiomyopathy and left ventricular dysfunction.Īetna considers PET for absolute quantitation of myocardial blood flow (AQMBF) experimental and investigational because the value of this test in guiding management has not been established.įDG-PET is considered medically necessary to identify and monitor response to therapy for established or strongly suspected cardiac sarcoid. The identification of members with partial loss of heart muscle movement or hibernating myocardium is important in selecting candidates with compromised ventricular function to determine appropriateness for re-vascularization. The greater specificity of PET makes a SPECT following an inconclusive PET not medically necessary. For use in assessment of coronary artery disease after cardiac transplant.įluorodeoxy-D-glucose (FDG)-PET scans are considered medically necessary for the determination of myocardial viability prior to re-vascularization, either as a primary or initial diagnostic study or following an inconclusive SPECT.The PET scan is used in place of, but not in addition to, a single photon emission computed tomography (SPECT), in persons who meet medical necessity criteria for a cardiac SPECT (see CPB 0376 Single Photon Emission Computed Tomography (SPECT)) or.PET scans using rubidium-82 (Rb-82) or N-13 ammonia done at rest or with pharmacological stress are considered medically necessary for non-invasive imaging of the perfusion of the heart for the diagnosis and management of members with known or suspected coronary artery disease, provided such scans meet either one of the two following criteria: The Program, as well as the prices and the list of covered drugs, can be modified at any time without notice.Aetna considers positron emission tomography (PET) medically necessary for the following cardiac indications: The day supply is based upon the average dispensing patterns for the specific drug and strength. Discount percentages represent savings provided off of pharmacies’ retail prices for consumers who do not have a discount program and pay cash. *Average and up to savings percentages are based on all discounted prescriptions that were run through the WellRx program in 2020. This program is administered by Medical Security Card Company, LLC, Tucson, AZ. You may contact customer care anytime with questions or concerns, to cancel your registration, or to obtain further information.
Cannot be used in conjunction with insurance. Members are required to pay for all prescription purchases. This program does not make payments directly to pharmacies. The range of the discounts will vary depending on the type of prescription and the pharmacy chosen. Discounts are available exclusively through participating pharmacies. The pricing estimates given are based on the most recent information available and may change based on when you actually fill your prescription at the pharmacy.ĭISCOUNT ONLY - NOT INSURANCE. Prescription prices may vary from pharmacy to pharmacy and are subject to change.
0 kommentar(er)
